Progress towards eliminating Hib in Australia: An evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000
DOI:
https://doi.org/10.33321/cdi.2003.27.57Keywords:
disease surveillance, disease control, Haemophilus influenzae, immunisation, vaccinationAbstract
The status of Haemophilus influenzae (Hib) disease and its prevention by vaccination was reviewed for the period 1997 to 2000. This forms the background to a change in national vaccine policy, from the use of two Hib vaccines to the use of PRP-OMP only throughout Australia from May 2000. Notifications of Hib in the 7-year period between 1993 and 2000 declined by 87 per cent among children 0-4 years of age; adjustment for likely under-reporting increase this to a 95 per cent reduction. Among age groups not included in the immunisation program, there was also a substantial decline in notified cases. Overall, a minimum 430 cases and 13 deaths were prevented by Hib immunisation annually in Australia. Enhanced Hib surveillance recorded 532 cases over seven years, with 353 in unvaccinated persons, 74 fulfilling criteria for true vaccine failure and 75 partially immunised. Of unvaccinated cases, 60 and 182 were eligible for routine and catch-up immunisation respectively. Although the overall incidence for 0-4 years of age declined from 15 to 1.2 cases per 100,000 population, the proportion of cases under six months of age increased from 11 per cent to 23 per cent. Overall vaccine effectiveness, estimated using data from the last five years of the program, was 83 per cent (95% CI 71-91%), increasing to 90 per cent (95% CI 83-94%) when adjusted for under-reporting to the Australian Childhood Immunisation Register. Among Aboriginal and Torres Strait Islander people, the incidence of invasive Hib disease fell from 4.6 cases per 100,000 population to 0.7 cases per 100,000 population but the proportion of cases now occurring among Aboriginal or Torres Strait Islander people increased significantly, from 7 to 15 per cent. The Hib immunisation program in Australia has been highly successful. Nevertheless, experience in Australia and elsewhere indicates that continued careful monitoring of Hib disease, with high quality laboratory surveillance, remains important. Commun Dis Intell 2003;27:324-341.
Downloads
References
Koo W, Oley C, Munro R, Tomlinson P. Systemic Haemophilus influenzae infection in childhood. Med J Aust 1982;2:77-80.
McGregor AR, Bell JM, Abdool IM, Collignon PJ. Invasive Haemophilus influenzae infection in the Australian Capital Territory region. Med J Aust 1992;156:569-572.
Hanna JN. The epidemiology of invasive Haemophilus influenzae infections in children under five years of age in the Northern Territory: a three-year study. Med J Aust 1990;152:234-236, 238, 240.
Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. [Review] Clin Microbiol Rev 2000;13:302-317.
Hanna JN, Wild BE. Bacterial meningitis in children under five years of age in Western Australia. Med J Aust 1991;155:160-164.
McIntyre PB, Leeder SR, Irwig LM. Invasive Haemophilus influenzae type b disease in Sydney children 1985 to 1987: a population-based study. Med J Aust 1991;154:832-837.
Harris A, Hendrie D, Bower C, Payne J, de Klerk, Stanley F. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. Med J Aust 1994;160:483-488.
Gilbert GL, Clements DA, Broughton SJ. Haemophilus influenzae type b infections in Victoria, Australia, 1985 to 1987. Pediatr Infect Dis J 1990;9:252-257.
Markey P, Krause V, Boslego JW, Coplan PM, Dargan JM, Kaplan KM. The effectiveness of Haemophilus influenzae type b conjugate vaccines in a high risk population measured using immunization register data. Epidemiol Infect 2001;126:31-36.
Peltola H, Kayhty H, Sivonen A, Makela H. Haemophilus influenzae type b capsular polysac- charide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977;60:730-737.
McIntyre P. Invasive Haemophilus influenzae type b disease. Aust Fam Physician 1993;22:1782-1789.
McIntyre PB, Chey T, Smith WT. The impact of vaccination against invasive Haemophilus influenzae type b disease in the Sydney region. Med J Aust 1995;162:245-248.
Shapiro ED, Ward JI. The epidemiology and prevention of disease caused by Haemophilus influenzae type b. [Review] Epidemiol Rev 1991;13:113-142.
Annual report of the National Notifiable Disease Surveillance System, 1993. Commun Dis Intell 1994;18:518-548.
Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 1993;22:742-746.
Clements DA, Guise IA, MacInnes SJ, Gilbert GL. Haemophilus influenzae type b infections in Victoria, Australia, 1985 to 1989. J Infect Dis 1992;165 Suppl 1:S33-S34.
Gilbert GL. Epidemiology of Haemophilus influenzae type b disease in Australia and New Zealand. Vaccine 1991;9 Suppl:S10-3; discussion S25.
Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988;10:212-241.
Hull B, Lawrence G, MacIntyre CR, McIntyre P. Immunisation coverage: Australia 2001. Canberra: Commonwealth Department of Health and Ageing; 2002.
Herceg A. The decline of Haemophilus influenzae type b disease in Australia Commun Dis Intell 1997:21:173-176.
Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children-United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002;51:234-237.
Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002;86:396-399.
Moulton LH, Chung S, Croll J, Reid R, Weatherholtz RC, Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol 2000;29:753-756.
Millar EV, O'Brien KL, Levine OS, Kvamme S, Reid R, Santosham M. Toward elimination of Haemophilus influenzae type b carriage and disease among high-risk American Indian children. Am J Public Health 2000;90:1550-1554.
Rushdy A, Ramsay M, Heath PT, Azzopardi HJ, Slack MP. Infant Hib vaccination and herd immunity. J Pediatr 1999;134:253-254.
Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995;171:93-98.
Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis 1998;177:1758-1761.
Forleo-Neto E, de Oliveira CF, Maluf EM, Bataglin C, Araujo JM, Kunz LF Jr, et al. Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria-tetanus toxoids-pertussis vaccine. J Infect Dis 1999;180:1153-1158.
Handford S, Andrews N, Rushdy A, Ramsay M, Slack M, Heath P. An evaluation of Haemophilus influenzae type b (Hib) vaccination and description of risk factors for Hib vaccine failure in Europe 1996-1999. Final Report. London: PHLS Communicable Disease Surveillance Centre; 2002.
Claesson BA. Epidemiology of invasive Haemophilus influenzae type b disease in Scandinavia. Vaccine 1993;11 Suppl 1:S30-S33.
Booy R, Hodgson SA, Slack MP, Anderson EC, Mayon-White RT, Moxon ER. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-91). Arch Dis Child 1993;69:225-228.
Anderson EC, Begg NT, Crawshaw SC, Hargreaves RM, Howard AJ, Slack MP. Epidemiology of invasive Haemophilus influenzae infections in England and Wales in the pre-vaccination era (1990-2). Epidemiol Infect 1995;115:89-100.
Singleton R, Bulkow LR, Levine OS, Butler JC, Hennessy TW, Parkinson A. Experience with the prevention of invasive Haemophilus influenzae type b disease by vaccination in Alaska: the impact of persistent oropharyngeal carriage. J Pediatr 2000;137:313-320.
Galil K, Singleton R, Levine OS, Fitzgerald MA, Bulkow L, Getty M, et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999;179:101-106.
Bower C, Condon R, Payne J, Burton P, Watson C, Wild B. Measuring the impact of conjugate vaccines on invasive Haemophilus influenzae type b infection in Western Australia. Aust N Z J Public Health 1998;22:67-72.
Hanna JN, Wild BE, Sly PD. The epidemiology of acute epiglottitis in children in Western Australia. J Paediatr Child Health 1992;28:459-464.
Smith-Vaughan HC, McBroom J, Mathews JD. Modelling of endemic carriage of Haemophilus influenzae in Aboriginal infants in Northern Australia. FEMS Immunol Med Microbiol 2001;31:137-143.
Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. [Erratum in Lancet 1997;349:1630.] Lancet 1997;349:1197-1202.
Coen PG, Heath PT, Garnett GP. The Hib immunization programme in the Oxford region: an analysis of the impact of vaccine administration on the incidence of disease. Epidemiol Infect 1999;123:389-402.
Heath PT, Booy R, Griffiths H, Kimball A, Hindiyeh M, Carroll K, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis 2000;31:973-980.
Adderson EE, Byington CL, Spencer L, et al. Invasive serotype a Haemophilus influenzae infections with a virulence genotype resembling Haemophilus influenzae type b: emerging pathogen in the vaccine era? Pediatrics 2001;180:E18.
Downloads
Published
How to Cite
License
Copyright (c) 2003 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
